|  | | RMST at times (years) | | | | Survival proportions at times (years) | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Source | 4 | 8 | 15 | LE | 4 | 8 | 15 | Lifetime |
| **FC** | **Observed** | **3.56** | **5.99** |  |  | **0.77** | **0.41** |  |  |
|  | Semi-Markov: SPM, ASF (Williams 2017) | 3.60 | 5.74 | 6.77 | 6.95 | 0.75 | 0.32 | 0.05 | 0.00 |
|  | Semi-Markov: FPM, ASF | 3.63 | 6.11 | 8.25 | 10.45 | 0.78 | 0.47 | 0.20 | 0.00 |
|  | Microsimulation: SPM, ASF | 3.51 | 5.59 | 6.82 | 7.20 | 0.72 | 0.33 | 0.08 | 0.00 |
|  | Microsimulation: FPM, ASF | 3.51 | 5.86 | 8.16 | 11.66 | 0.72 | 0.45 | 0.25 | 0.00 |
|  | Microsimulation: FPM, RSF | 3.52 | 5.86 | 8.08 | 10.06 | 0.72 | 0.45 | 0.23 | 0.00 |
| **RFC** | **Observed** | **3.68** | **6.54** |  |  | **0.84** | **0.61** |  |  |
|  | Semi-Markov: SPM, ASF (Williams 2017) | 3.62 | 5.78 | 6.82 | 6.99 | 0.76 | 0.32 | 0.05 | 0.00 |
|  | Semi-Markov: FPM, ASF | 3.62 | 6.07 | 8.22 | 10.41 | 0.77 | 0.46 | 0.19 | 0.00 |
|  | Microsimulation: SPM, ASF | 3.63 | 5.82 | 6.81 | 6.99 | 0.77 | 0.32 | 0.05 | 0.00 |
|  | Microsimulation: FPM, ASF | 3.62 | 6.12 | 8.24 | 10.39 | 0.77 | 0.47 | 0.20 | 0.00 |
|  | Microsimulation: FPM, RSF | 3.62 | 6.12 | 8.17 | 9.55 | 0.77 | 0.46 | 0.18 | 0.00 |
| RMST, restricted mean survival time; LE, life expectancy; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; SPM, standard parametric models; FPM, flexible parametric models; ASF, all-cause survival framework; RSF, relative survival framework. | | | | | | | | | |